

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1.-13. (CANCELLED)

14. (NEW) A DNA transfer vector containing a sequence coding for a fragment, wherein said sequence is selected from the group consisting of SEQ ID N. 1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14.

15. (NEW) A DNA transfer vector according to claim 14, which is a plasmid.

16. (NEW) The DNA transfer vector of claim 15, further containing a transcription promotor.

17. (NEW) The DNA transfer vector of claim 16, wherein the promotor is CMV.

18. (NEW) The DNA transfer vector of claim 15, further containing 4 CpG motifs.

19. (NEW) The DNA transfer vector of claim 18, further containing 8 CpG motifs.

20. (NEW) A Pharmaceutical composition containing a DNA transfer vector according to claim 14 in admixture with pharmaceutically acceptable vehicles and excipients.

21.(NEW) The composition according to claim 7, which is in a form for parenteral administration.

22.(NEW) The composition of claim 8, which is in the form of an injectable solution.

23.(NEW) A combined pharmaceutical preparation containing at least two different DNA transfer vectors according to claim 14, for simultaneous, sequential or separate therapeutic use.

24.(NEW) A combined preparation according to claim 23, which is in a form suitable for DNA vaccination.

25.(NEW) A method for the preventive or therapeutical treatment of subject at risk of developing pi positive tumours, or having primary tumours, metastasis or relapses tumours, comprising administering to said subject an affective amount of a DNA transfer vector according to claim 14.

26.(NEW) The use according to claim 25, for the preparation of a DNA vaccine.